Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Concurrent Chemoradiation (Cisplatin-based)
Treatment for Cervical cancer
Typical Dosage: Cisplatin 40mg/m² weekly for 5-6 cycles, plus EBRT and brachytherapy
Effectiveness
85%
Safety Score
25%
Clinical Trials
67
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Cisplatin 40mg/m² weekly for 5-6 cycles, plus EBRT and brachytherapy
Time to Effect
During and shortly after treatment
Treatment Duration
5-7 weeks
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,000
Monitoring:$10,000
Side Effect Mgmt:$6,000
Total Annual:$50,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
3
Outcome-Based Costs
Cost per Responder
$62,500
Cost per Remission
$76,923
Comparison vs Radiation Therapy alone
Cost Difference
+$15,000/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Concurrent Chemoradiation (Cisplatin-based) Outcomes
for Cervical cancer
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+80%
Remission Rate
+65%
Common Side Effects
Fatigue
+85%
Nausea/Vomiting
+75%
Diarrhea/Proctitis
+60%
Cystitis
+40%
Bone marrow suppression
+50%
Peripheral neuropathy
+30%
Sexual dysfunction/Vaginal stenosis
+60%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
10 active trials recruiting for Concurrent Chemoradiation (Cisplatin-based) in Cervical cancer
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer
NCT05492123RECRUITINGPHASE2
112 participants
INTERVENTIONAL
Fortaleza, Brazil +13 more
Started: Aug 30, 2022
Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer
NCT07244965NOT YET RECRUITINGPHASE2
42 participants
INTERVENTIONAL
Hangzhou, China
Started: Dec 1, 2025
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03919552RECRUITINGPHASE3
482 participants
INTERVENTIONAL
Guangzhou, China
Started: Jan 31, 2018
Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)
NCT05872724RECRUITINGPHASE2
32 participants
INTERVENTIONAL
Suzhou, China
Started: Jan 16, 2023
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
NCT05628922RECRUITINGPHASE2
198 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 2, 2022
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
NCT06288373RECRUITINGPHASE2, PHASE3
440 participants
INTERVENTIONAL
Hefei, China +11 more
Started: Apr 22, 2024
PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy
NCT05980715RECRUITINGPHASE3
324 participants
INTERVENTIONAL
Guangzhou, China
Started: Jan 1, 2023
Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer
NCT04178174RECRUITINGPHASE3
360 participants
INTERVENTIONAL
London, Canada +1 more
Started: Feb 23, 2020
Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer
NCT03617133RECRUITINGPHASE2
1K participants
INTERVENTIONAL
Vienna, Austria
Started: Apr 1, 2016
Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging
NCT03865277NOT YET RECRUITINGPHASE2
276 participants
INTERVENTIONAL
Freiburg im Breisgau, Germany +7 more
Started: Jul 1, 2024
Completed Clinical Trials
5 completed trials for Concurrent Chemoradiation (Cisplatin-based) in Cervical cancer
Induction Chemotherapy for Advanced Head and Neck Cancer
NCT00959387COMPLETEDPHASE2
60 participants
INTERVENTIONAL
Barretos, Brazil
Started: Aug 1, 2009
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
NCT00424255COMPLETEDPHASE3
688 participants
INTERVENTIONAL
Springfield, United States +116 more
Started: Dec 1, 2006
An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.
NCT03998696COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Dhaka, Bangladesh
Started: Jul 1, 2017
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
NCT02107235COMPLETEDPHASE1
2 participants
INTERVENTIONAL
Aurora, United States +3 more
Started: Jan 1, 2014
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
NCT03830866COMPLETEDPHASE3
770 participants
INTERVENTIONAL
Phoenix, United States +116 more
Started: Feb 15, 2019
Showing 20 of 76 total trials